nezulcitinib

a lung-selective pan-Janus-associated kinase (JAK) inhibitor

Also Known As:

(S)-(3-(dimethylamino)azetidin-1-yl)(2-(6-(2-ethyl-4-hydroxyphenyl)-1H-indazol-3-yl)-5-isopropyl-4,5,6,7-tetrahydro-3H-imidazo(4,5-c)pyridin-6-yl)methanone; TD-0903; TD-0903 monohydrate; THRX-136377; THRX-136377 monohydrate; methanone, (3-(dimethylamino)-1-azetidinyl)((6S)-2-(6-(2-ethyl-4-hydroxyphenyl)-1H-indazol-3-yl)-4,5,6,7-tetrahydro-5-(1-methylethyl)-3H-imidazo(4,5-C)pyridin-6-yl)-, hydrate (1:1); nezulcitinib monohydrate

Networked: 5 relevant articles (0 outcomes, 3 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indazoles: 179
      - nezulcitinib: 5

Experts

1.	Bourdet, David L: 2 articles (11/2021 - 10/2021)
2.	Pfeifer, Nathan D: 2 articles (11/2021 - 10/2021)
3.	Singh, Dave: 2 articles (11/2021 - 10/2021)
4.	Constantinescu, Stefan N: 1 article (01/2022)
5.	Guglielmelli, Paola: 1 article (01/2022)
6.	Langmuir, Peter: 1 article (01/2022)
7.	Levy, Gabriel: 1 article (01/2022)
8.	Colley, Kenneth: 1 article (11/2021)
9.	Doumas, Michael: 1 article (11/2021)
10.	Karagiannis, Asterios: 1 article (11/2021)

Related Diseases

1.	COVID-19 11/01/2021 - "Phase I study in healthy participants to evaluate safety, tolerability, and pharmacokinetics of inhaled nezulcitinib, a potential treatment for COVID-19." 01/01/2023 - "Further studies are required to determine if treatment with nezulcitinib confers clinical benefit in specific inflammatory biomarker-defined populations of patients with COVID-19." 01/01/2023 - "The inhaled lung-selective pan-Janus kinase inhibitor nezulcitinib had favourable safety and potential efficacy signals in part 1 of a phase 2 trial in patients with severe COVID-19, supporting progression to part 2. Part 2 was a randomised, double-blind phase 2 study (NCT04402866). " 10/01/2021 - "A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19." 01/01/2023 - "Efficacy and safety of an inhaled pan-Janus kinase inhibitor, nezulcitinib, in hospitalised patients with COVID-19: results from a phase 2 clinical trial."
2.	Acute Lung Injury 11/01/2021 - "Nezulcitinib (TD-0903), a lung-selective pan-Janus-associated kinase (JAK) inhibitor designed for inhaled delivery, is under development for treatment of acute lung injury associated with coronavirus disease 2019 (COVID-19). "
3.	Infections 11/01/2021 - "We finally pooled data of interest from 4 RCTs in a total of 1338 subjects with documented COVID-19 infection, utilizing the following JAK inhibitors: baricitinib, ruxolitinib, tofacitinib, and nezulcitinib. "

Related Drugs and Biologics

1.	Janus Kinase Inhibitors
2.	Biomarkers (Surrogate Marker)
3.	ruxolitinib
4.	tofacitinib
5.	baricitinib
6.	Phosphotransferases (Kinase)
7.	Oxygen (Dioxygen)
8.	Adrenal Cortex Hormones (Corticosteroids)

Related Therapies and Procedures

1.	Therapeutics
2.	Artificial Respiration (Mechanical Ventilation)